| Sign In to gain access to subscriptions and/or personal tools. |
DOI: 10.1177/1358836X9900400307 Platelets and strokeDepartment of Medicine, King’s College School of Medicine and Dentistry, London
Department of Medicine, King’s College School of Medicine and Dentistry, London
Department of Medicine, King’s College School of Medicine and Dentistry, London, Division of Stroke Medicine, University of Nottingham, Nottingham, UK Platelets are anucleate cells with little or no capacity for de novo protein synthesis. Their potential haemostatic reactivity is established at or before thrombopoiesis by their precursor cell, the bone marrow megakaryocyte. In some pathologic conditions, the megakaryocyte-platelet-haemostatic axis (MPHA) becomes perturbed, resulting in the formation of hyperfunctional platelets which may contribute to the development of vascular disease or an acute thrombotic event such as ischaemic stroke or myocardial infarction. Laboratory measurements of platelet function have established that platelet reactivity is accentuated in acute ischaemic stroke, particularly following cortical rather than lacunar infarction. Whether accentuated platelet function is a cause or a consequence of stroke is not yet clear, but it is likely that patients with certain risk factor profiles have some degree of platelet activation preceding the stroke. Further work into the MPHA is required to establish whether enhanced post-stroke platelet reactivity can be referred to the megakaryocyte. The antiplatelet agents tested to date are effective in secondary but not primary prevention of stroke. This probably reflects the diverse patho-physiology of stroke: accentuated platelet function is only likely to be a significant factor in cortical stroke.
Key Words: antiplatelet agents • megakaryocytes • platelets • stroke
This article has been cited by other articles:
|
||||||||||||||||||||||||
 |
|
|
 |
 |
Sign In to gain access to subscriptions and/or personal tools.
